Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals develops new antibiotics for hard to treat bacterial infections, based in Staten Island, New York. It last closed at $0.99 on Nov 17, up 5.88% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From ACXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on ACXP in the past 90 days. The average target is $11.00, with a high of $11.00 and a low of $11.00, compared with the last close of $0.99.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 12 | HC Wainwright & Co. | Target lowered | Buy | $31 → $11 |
| Sep 29 | HC Wainwright & Co. | Reiterated | Buy | $31 |
Technical Analysis
The stock is 5% below its 20 day and 21% below its 50 day average. It is 90% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot S1 at $0.95, and the nearest resistance the Pivot R1 at $1.03.
| RSI (14) | 39.34 | Weak, oversold below 30 | Neutral |
| MACD | -0.06 | Below its signal line | Bearish |
| Stochastic | 21.3 | Middle of its range | Neutral |
| ADX (14) | 39.8 | Trending down | |
| Williams %R | -64.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -107.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −2.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.08 | Typical daily range, 7.7% of price |
| RSI (14) | 33.79 | Weak, oversold below 30 | Neutral |
| MACD | -0.35 | Above its signal line | Bullish |
| Stochastic | 8.5 | Near the bottom of its range | Oversold |
| ADX (14) | 9.6 | No clear trend | |
| Williams %R | -91.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -141.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −29.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.31 | Typical daily range, 30.9% of price |
What happened before
See how ACXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ACXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ACXP in the last 90 days.
ACXP Institutional Ownership
Full report →- ▼6 buying vs 8 selling
- ▲Held by funds +0.9 pts
- ●Funds holding +0
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 19 | 19 | 0.0% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 3.0% | 2.0% | +0.9 pts |
| New / increased | 3 / 3 | 2 / 3 | +20.0% |
| Reduced / sold out | 5 / 3 | 4 / 4 | 0.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACXP is in one of them and how their past ACXP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACXP in an article yet. Here's the latest on the wider market.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company based in Staten Island, New York. It is developing a new class of small molecule antibiotics for bacterial infections that are hard to treat, including Clostridioides difficile infections, MRSA, and vancomycin resistant Enterococcus. Its lead candidate, ibezapolstat, works by blocking a bacterial enzyme called DNA pol IIIC and is in clinical trials. The company expects to partner with a larger drugmaker for later stage trials and commercialization, and its intended users are patients with these infections and the healthcare providers who treat them.
- Headquarters
- Staten Island, NY